Company profile
XenoGesis is now part of Sygnature Discovery
XenoGesis is now part of Sygnature Discovery. Find us at sygnaturediscovery.com.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
AP01 | Transaction MzUxNjcwMzEwMGFkaXF6a2N4
Published 16 Apr 2026 17:59
AP01 | Transaction MzUxNjcwMzAxN2FkaXF6a2N4
Published 16 Apr 2026 17:57
TM01 | Transaction MzUxNjcwMjk3N2FkaXF6a2N4
Published 16 Apr 2026 17:56
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Oct 2014 to 30 Jun 2016
The Caco-2 cell line is the gold standard for the prediction of drug absorption and permeability in vitro by mimicking the small intestine. However, this model lacks the dynamic motion which represents one of the physiological functions of the small intestine (peristalsis). In our research, we investigate the possibility the similarity between the static ...
1 Sep 2014 to 30 Nov 2015
Non-alcoholic fatty liver disease (NAFLD) encompasses a range of conditions from fatty liver (steatosis) to non-alcoholic steatohepatitis (NASH). NAFLD is a condition affecting around 30 % of the general population and 70 % of obese and diabetic patients. The prevalence of NAFLD is set to rise as the obesity and diabetic pandemic escalates. It is therefor...
1 Apr 2013 to 30 Jun 2014
Inhalation is an increasingly important delivery approach of therapeutic agents to the lung. There remains an unmet medical, commercial and practical need for 'once-a-day' treatment in various therapeutic areas and this is lacking for some current therapies. Once daily treatment is possible in some cases, but this approach can involve over-dosing to give ...
